Inventor · disambiguated record
Matthias Schneider
Also filed as: SCHNEIDER MATTHIAS
19 granted patents·20 pending applications·41 citations·filing 1979–2024
92Inventor score
Files withDAIICHI SANKYO CO LTD7ALANTOS PHARM HOLDING6SCIRHOM GMBH4SCHERING AG3ALANTOS PHARMACEUTICALS INC2
Top patents by PatentIndex Score
39 records- 0186US7417056B25-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agentsSCHERING AG·Filed 2005·Granted Aug 26, 2008·6 cites·32 claims
- 0282USRE45499EN-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph BBAYER IP GMBH·Filed 2014·Granted Apr 28, 2015·6 cites·21 claims
- 0381US12497666B2Nucleic acid biomarker and use thereofDAIICHI SANKYO CO LTD·Filed 2023·Granted Dec 16, 2025·0 cites·8 claims
- 0476US8076330B2Dipeptidyl peptidase-IV inhibitorsKROTH HEIKO·Filed 2011·Granted Dec 13, 2011·4 cites·24 claims
- 0575US7973166B2N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph BBAYER SCHERING PHARMA AG·Filed 2009·Granted Jul 5, 2011·2 cites·21 claims
- 0673US9637542B2CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of diseaseWATERMAN ALISA K·Filed 2014·Granted May 2, 2017·2 cites·16 claims
- 0772US12404345B2Humanized antibodies against iRHOM2SCIRHOM GMBH·Filed 2024·Granted Sep 2, 2025·0 cites·24 claims
- 0872US11840736B2Nucleic acid biomarker and use thereofDAIICHI SANKYO CO LTD·Filed 2019·Granted Dec 12, 2023·0 cites·14 claims
- 0972US8835441B2Heterobicyclic metalloprotease inhibitorsSTEENECK CHRISTOPH·Filed 2011·Granted Sep 16, 2014·3 cites·10 claims
- 1070US7713966B2Heterobicyclic metalloprotease inhibitorsALANTOS PHARM HOLDING·Filed 2007·Granted May 11, 2010·1 cites·12 claims
- 1169US11873344B2Protein biomarker and uses thereofDAIICHI SANKYO CO LTD·Filed 2019·Granted Jan 16, 2024·0 cites·12 claims
- 1269US7795245B2Heterobicyclic metalloprotease inhibitorsATLANTOS PHARMACEUTICALS HOLDI·Filed 2007·Granted Sep 14, 2010·2 cites·15 claims
- 1365US7749996B2Heterotricyclic metalloprotease inhibitorsALANTOS PHARMACEUTICAL HOLDING·Filed 2007·Granted Jul 6, 2010·1 cites·14 claims
- 1464US2010087420A1Heterotricyclic Metalloprotease InhibitorsALANTOS PHARM HOLDING·Filed 2009·Application pending·0 cites
- 1561US2009312312A1Heterobicyclic Metalloprotease InhibitorsALANTOS PHARM HOLDING·Filed 2009·Application pending·0 cites
- 1660US6784292B2Method for the production of imidazo-(1,2-C)(2,3)-benzodiazepines and intermediates in the production thereofSCHERING AG·Filed 2001·Granted Aug 31, 2004·2 cites·8 claims
- 1760US2010009961A1Dipeptidyl peptidase-iv inhibitorsALANTOS PHARM HOLDING·Filed 2009·Application pending·0 cites
- 1857US2015152508A1Nucleic acid biomarker and use thereofDAIICHI SANKYO CO LTD·Filed 2014·Application pending·0 cites
- 1956US9412044B2Method of compensation of respiratory motion in cardiac imagingSCHNEIDER MATTHIAS·Filed 2010·Granted Aug 9, 2016·1 cites·12 claims
- 2056US2024166767A1Humanized antibodies against irhom2SCIRHOM GMBH·Filed 2022·Application pending·0 cites
- 2156US2007155738A1Heterobicyclic metalloprotease inhibitorsALANTOS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2256US2015147326A1Protein biomarker and uses thereofDAIICHI SANKYO CO LTD·Filed 2014·Application pending·0 cites
- 2352US2008161300A1Heterobicyclic metalloprotease inhibitorsALANTOS PHARM HOLDING·Filed 2007·Application pending·0 cites
- 2450US2017166973A1Nucleic acid biomarker and use thereofDAIICHI SANKYO CO LTD·Filed 2016·Application pending·0 cites
- 2550US2011009654A111b-fluoro-3-acetoxyestra-3,5-dien-17-one and method for the production thereofPETROV ORLIN·Filed 2008·Application pending·0 cites
- 2650US2017166654A1Protein biomarker and uses thereofDAIICHI SANKYO CO LTD·Filed 2016·Application pending·0 cites
- 2748US2005262578A1Non-human animal models of atherosclerosis and methods of use thereofPITAS ROBERT E·Filed 2004·Application pending·0 cites
- 2848US2010249102A1Heterotricyclic Metalloprotease InhibitorsALANTOS PHARM HOLDING·Filed 2010·Application pending·0 cites
- 2947US2024174744A1Methods of treatment using protein binders to irhom2 epitopesSCIRHOM GMBH·Filed 2022·Application pending·0 cites
- 3046US11609231B2Detection of autoantibodies for diagnosing degenerative diseases of the skeletal systemUNIV KOELN·Filed 2018·Granted Mar 21, 2023·0 cites·14 claims
- 3145US2006293345A1Heterobicyclic metalloprotease inhibitorsSTEENECK CHRISTOPH·Filed 2006·Application pending·0 cites
- 3243US7462718B2Process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarateSCHERING AG·Filed 2004·Granted Dec 9, 2008·0 cites·15 claims
- 3343US2022204610A1Protein binders for irhom2NEW YORK SOC FOR THE RELIEF OF THE RUPTURED AND CRIPPLED MAINTAING HOSPITAL FOR SPECIAL SURGERY·Filed 2020·Application pending·0 cites
- 3440US2024287172A1Protein binders to irhom2 epitopesSCIRHOM GMBH·Filed 2020·Application pending·0 cites
- 3539US2006173183A1Multicyclic bis-amide MMP inhibitorsALANTOS PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 3639US2015293120A1Marker sequences for rheumatoid arthritisPROTAGEN AG·Filed 2013·Application pending·0 cites
- 3734US2013303395A1Marker sequences for systemic lupus erythematosus and the use thereofLUEKING ANGELIKA·Filed 2011·Application pending·0 cites
- 3828US10677795B2Marker sequences for the diagnosis and stratification of systemic sclerosis patientsPROTAGEN AG·Filed 2015·Granted Jun 9, 2020·0 cites·9 claims
- 3927US4210153AMedical diagnostic device for determining bleeding times and behavior of bleedings from a standardized woundHELLIGE GMBH·Filed 1979·Granted Jul 1, 1980·11 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Matthias Schneider files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →